Aktis Oncology initiates phase 1b trial for lung cancer drug

Aktis Oncology initiated the Phase 1b BActinium-2 trial of AKY-2519 in non-small cell lung cancer and other B7-H3-expressing solid tumors, expanding clinical development of its second pipeline program. The company is testing three dose levels with potential enrollment expansion, while preliminary data from its separate prostate-cancer study are expected in 2027. Aktis also continues enrolling its more advanced AKY-1189 radioconjugate trial, with initial data expected in Q1 2027.

Analysis

This is not a valuation-changing catalyst: a Phase 1b expansion primarily increases clinical optionality while also increasing cash burn, and the first disclosed efficacy readouts are too distant to support a fundamental rerating in the next 1-3 months. The key investment variable is not enrollment progress but whether future data establish a therapeutic window—tumor uptake and durable responses at doses that avoid hematologic, renal, and off-target radiation toxicity. Until dose-selection evidence emerges, assigning meaningful probability-weighted revenue to either radioconjugate program is premature.

There is a material identity and tradability issue: NASDAQ:AKTS has historically referred to Akoustis Technologies rather than Aktis Oncology. Investors should not transact in AKTS based on this release without confirming the issuer, listing status, capitalization, cash runway, and whether Aktis is publicly traded. LLY's collaboration creates only long-dated platform-validation optionality; it does not imply milestone recognition, royalty economics, or a near-term impact to Lilly's earnings. The more investable read-through, if radiopharmaceutical data validate miniprotein targeting, would likely accrue to established radiopharma platforms and isotope-supply beneficiaries rather than LLY.

Key Decisions for Investors

• No trade in AKTS until issuer/ticker identity is independently verified; treat any price move attributed to this announcement as a misinformation/liquidity risk rather than a clinical catalyst.
• Create a Q1-2027 alert for AKY-1189 preliminary data and a 2027 alert for AKY-2519 data. Require objective response rate, durability, dose-limiting toxicity, discontinuation rates, and dosimetry versus competing radiopharmaceutical approaches before underwriting value.
• Do not use LLY as a proxy long for this development. Reassess only if Lilly discloses economics, exercises an option, or commits material development capital; absent that, the revenue and EPS sensitivity is immaterial.
• If a verified public Aktis security emerges, wait for cash-runway disclosure and initial efficacy/safety data before entry; a defensible long would require at least 18 months of runway and evidence that selected doses can scale enrollment without unexpected toxicity.